Compare SHC & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHC | RYTM |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.9B |
| IPO Year | 2020 | 2017 |
| Metric | SHC | RYTM |
|---|---|---|
| Price | $15.35 | $84.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $20.67 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 2.6M | 960.8K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.75 | 28.34 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $1,163,617,000.00 | N/A |
| Revenue This Year | $7.51 | $54.90 |
| Revenue Next Year | $6.00 | $86.58 |
| P/E Ratio | $56.91 | ★ N/A |
| Revenue Growth | ★ 5.74 | N/A |
| 52 Week Low | $10.17 | $55.31 |
| 52 Week High | $19.85 | $122.20 |
| Indicator | SHC | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 58.45 | 44.36 |
| Support Level | $15.19 | $74.50 |
| Resistance Level | $16.55 | $93.51 |
| Average True Range (ATR) | 0.43 | 4.53 |
| MACD | 0.30 | 0.72 |
| Stochastic Oscillator | 95.94 | 57.76 |
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for medical device, pharmaceutical, food safety, and applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are the United States, Canada, Europe and other regions.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.